<DOC>
	<DOCNO>NCT01250587</DOCNO>
	<brief_summary>The purpose study determine safe effective dose range intravenous administration ( infusion ) PDC31 determine maximum tolerate dose PDC31 patient primary dysmenorrhea .</brief_summary>
	<brief_title>Dose-Finding Study PDC31 Patients With Primary Dysmenorrhea</brief_title>
	<detailed_description>This open-label , multi-centre , dose-escalating first-in-human Phase I study PDC31 patient primary dysmenorrhea aim determine maximum tolerate dose ( MTD ) PDC31 patient population .</detailed_description>
	<mesh_term>Dysmenorrhea</mesh_term>
	<criteria>Otherwise healthy female history primary dysmenorrhea Using effective birth control exclude intrauterine contraceptive device ( IUCD ) Must 18 year age old Must give write informed consent participate study Patients intrauterine contraceptive device use oral contraceptive within 3 month treatment study Patients confirm pelvic inflammatory disease , endometriosis adenomyosis Patients pregnant test positive baseline risk become pregnant study Patients breastfeed Patients hepatic renal function test great upper limit normal deem clinically significant Investigator screening Patients clinically significant medical psychiatric disorder serious medical condition within past 6 month opinion investigator , prohibit participation study Patients exposure investigational drug within 4 week prior screen</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Open label</keyword>
	<keyword>dose-finding Phase 1 study</keyword>
</DOC>